Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Extracorporeal or ex vivo removal of antibodies or immune...
Reexamination Certificate
2007-04-10
2007-04-10
Hoffman, Susan (Department: 1655)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Extracorporeal or ex vivo removal of antibodies or immune...
C426S425000, C530S419000
Reexamination Certificate
active
10444606
ABSTRACT:
Methods for producing biological solutions such as immunoglobulins and in particular anti-D immunoglobulin substantially free of abnormal prion protein resulting therefrom. Specifically provided are methods for aggregation of prions and depth filtration of the biological solution to capture and remove abnormal and if desired, normal prion protein. The prion protein may then be eluted from the depth filter and filter washes and concentrated sufficient for detection at limits currently required by available assays.
REFERENCES:
patent: 2390074 (1945-12-01), Cohn
patent: 3449314 (1969-06-01), Pollack
patent: 3916026 (1975-10-01), Stephan
patent: 4021540 (1977-05-01), Pollack et al.
patent: 4141887 (1979-02-01), Seafert
patent: 4590002 (1986-05-01), Zolton et al.
patent: 4859340 (1989-08-01), Hou et al.
patent: 4880913 (1989-11-01), Doleschel et al.
patent: 5115101 (1992-05-01), Bloom et al.
patent: 5215681 (1993-06-01), Truong et al.
patent: 5723123 (1998-03-01), Karges et al.
patent: 5858641 (1999-01-01), Shanbrom
patent: 6096872 (2000-08-01), Van Holten et al.
patent: 6166187 (2000-12-01), Prusiner et al.
patent: 6221614 (2001-04-01), Prusiner et al.
patent: 6270672 (2001-08-01), Turecek et al.
patent: 6916419 (2005-07-01), Prusiner et al.
patent: WO 96/00237 (1996-01-01), None
patent: WO 98/08603 (1998-03-01), None
patent: WO 00/43048 (2000-07-01), None
patent: WO 00/43782 (2000-07-01), None
Roberts, Peter L., “Value of Virus Filtration as a Method for Improving the Safety of Plasma Products”, Vox Sang 1995;69;82-83.
DiLeo, Anthony J. et al., “Size Exclusion Removal of Model Mammalian Viruses Using a Unique Membrane System, Part 1: Membrane Qualification”, Biologicals (1993)21, 275-286.
Tateishi, Jun et al., “Removal of Causative Agent of Cruetzfeldt-Jakob Disease (CJD) Through Membrane Filtration Method”, (Original Contribution) (Membrane), 18(6), 357-362 (1993).
Burnouf, T., Value of Virus Filtration as a Mehod for Improving the Safety of Plasma Products, Vox San 1996;70:235-236.
Oncley, J.L. et al., The Separation of the Antibodies, Isoagglutinins, Prothrombin, Plasminogen and β1-Lipoprotein into Subfractions of Human Plasma, Feb. 1949 vol. 71, pp. 541-550.
Bridonneau, P. et al., “Liquid Pasteurization of an Immunoglobulin Preparation without Stabilizer: Effects on its Biological and Biochemical Properties”, Vox San 1996:70;203-209.
Tomasi, Thomas, Immunobiology, Current Knowledge of Basic Concepts in Immunology and Their Clinical Applications, The Gamma A Globulins: First Line of Defense, pp. 76-83.
Hardy, R.R., “Purification and characterization of monoclonal antibodies”, Handbook of Experimental Immunology in Four Volumes.
Dortand's Illustrated Medical Dictionary, Immunodeficiency Disorders, Diseases, and syndromes.
Van Holten, R.W. et al., Incorporation of Viral Clearance Step into a Modified Cohen Fractionation, Transfusion, 1995-vol. 35, Supplement.
Physicians' Desk Reference MICRhoGAM.
PCT International Search Report, dated Sep. 3, 2004, for PCT Int'l. Appln. No. PCT/US03/16347.
Prusiner, S. B., “Prion Encephalopathies of Animals and Humans”,Developments in Biological Standardization, 1993, 80: 31-34, S. Karger AG, Switzerland.
Turner, M. L., et al., “New-Variant Creutzfeldt-Jakob Disease: The Risk of Transmission by Blood Transfusion”,Blood Reviews, , 1998, 12: 255-268, Churchill Livingstone, Edinburgh.
Burnouf, T., et al., “Reducing the Risk of Infection from Plasma Products: Specific Preventative Strategies”,Blood Reviews, 2000, 14: 94-110, Harcourt Publishes Ltd.
Foster, P. R., “Assessment of the Potential of Plasma Fractionation Processes to Remove Causative Agents of Transmissible Spongiform Encephalopathy”, Transfusion Medicine, 1999, 9: 3-14.
Lee, Douglas C., et al., “Monitoring Plasma Processing Steps With a Sensitive Western Blot Assay for the Detection of the Prion Protein”, JVMEDH, 2000, 84(1), 77-89.
Foster, Peter R., et al., “Studies on the Removal of Abnormal Prior Protein by Processes Used in the Manufacture of Human Plasma Products”, Vox Sanguinis, 2000, 78: 86-95.
Lee, Douglas C., et al., “A Direct Relationship Between the Partitioning of the Pathogenic Prion Protein and the Transmissible Spongiform Encephalopathy Infectivity During the Purification of Plasma Proteins”, Transfusion , 2001, 41(4), 449-455.
Cohn, E. J., et al., “Preparation and Properties of Serum and Plasma Proteins. IV. A System for the Separation into Fractions of the Proteins and Lipoprotein Components of Biological Tissues and Fluids”, J. Am Chem. Soc., 1946, 68, 459.
Shaked, Gideon M., et al., “A Protease-Resistant Prion Protein Isoform Is Present in Urine of Animals and Humans Affected with Prion Diseases”, J. Biol. Chem. , 2001, 276(34), 31479-31482.
Prusiner, Stanley B., et al., “Molecular Properties, Partial Purification, and Assay by Incubation Period Measurements of the Hamster Scrapie Agent”, Biochemistry, 1980, 19, 4883-4891.
Winklhofer, Konstanze F., et al., “A Sensitive Filter Retention Assay for the Detection of PrPscand the Screening of Anti-Prion Compounds”, FEBS Letters 2001, 503: 41-45.
Wadsworth, J.D.F., et al., “Tissue Distribution of Protease Resistant Prion Protein in Variant Creutzfeldt-Jakob Disease Using a Highly Sensitive Immunoblotting Assay”, Lancet, 2001, 358: 171-180.
Safar, Jiri, et al., “Eight Prion Strains Have PrPscMolecules With Different Conformations”, Nature Medicine, 1998, 4(10): 1157-1165.
MacGregor, I, “Prion Protein and Developments in its Detection”, Transfusion Medicine, 2001, 11: 3-14.
Pocchiari, Maurizio, et al., “Combination Ultrafiltration and 6MUrea Treatment of Human Growth Hormone Effectively Minimizes Risk From Potential Creutzfeldt-Jakob Disease Virus Contamination”, Horm. Res, 1991, 35: 161-166.
Gölker, C. F., et al., Reduction of the Infectivity of Scrapie Agent as a Model for BSE in the Manufacturing Process of Trasylok®, Biologicals, 1996, 24: 103-111.
Saborio, Gabriela P., et al., “Sensitive Detection of Pathological Prion Protein by Cyclic Amplification of Protein Misfolding”, Nature, 2001, 411: 810-813.
Prowse, C. V., “Preliminary Assessment of Whole-Blood, Red-Cell and Platelet-Leucodepleting Filters for Possible Induction of Prion Release By Leucocyte Fragmentation During Room Temperature Processing”, British Journal of Haematology, 1999, 106: 240-247.
“EMEA Expert Workshop on Human TSEs and Plasma-Derived Medicinal Products”, The European Agency for the Evaluation of Medicinal ProductsEvaluation of Medicines for Human Use, CPMP/BWP/1244/00, 1-13, London, 2000.
Van Holten, Robert W., et al., “Removal of Prion Challenge From an Immune Globulin Preparation By Use of a Size-Exclusion Filter”, Transfusion, 2002, 42: 999-1004.
Van Holten, Robert et al., “Evaluation of Depth Filtration to Remove Prion Challenge From an Immune Globulin Preparation”, Vox Sanguinis, 2003, 85: 20-24.
Autenrieth Stephen M.
Van Holten Robert W.
Hoffman Susan
Ortho-Clinical Diagnostics, Inc.
Winston Randall
LandOfFree
Capture, concentration and quantitation of abnormal prion... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Capture, concentration and quantitation of abnormal prion..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Capture, concentration and quantitation of abnormal prion... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3745052